Dr. Kansagra on Remaining Questions With CAR T-Cell Therapy in Multiple Myeloma

Video

Ankit Kansagra, MD, discusses remaining questions with CAR T-cell therapy in multiple myeloma.

Ankit Kansagra, MD, assistant professor, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses remaining questions with CAR T-cell therapy in multiple myeloma.

CAR T-cell therapy has shown unprecedented activity in multiple myeloma, explains Kansagra.

Combining CAR T-cell therapy with other drugs may improve T-cell persistence; however, investigational combinations are still in preclinical stages of research, says Kansagra. CAR T-cell therapy could also show enhanced responses earlier on in treatment. As such, several trials are evaluating CAR T-cell therapy in the early relapse setting rather than in heavily pretreated patient populations.

Furthermore, little is known about the optimal treatment for patients who progress on CAR T-cell therapy. This is an area of unmet need that requires further investigation, concludes Kansagra.

Related Videos
Vivien Sheehan, MD, PhD, an associate professor of pediatrics at Emory University
Deepak L. Bhatt, MD, MPH, MBA
John A. Charlson, MD
Jeffrey Chamberlain, PhD
David Porter, MD
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Jonathan W. Weinsaft, MD
Omid Hamid, MD
Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital
Robert J. Hopkin, MD
© 2024 MJH Life Sciences

All rights reserved.